# Kidney Graft Function Under the Immunosuppression Strategies

> **NCT01817322** · PHASE4 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 140 (actual)

## Conditions studied

- Chronic Renal Disease

## Interventions

- **DRUG:** Standard Dose of Myfortic and Reduced Dose of Myfortic
- **DRUG:** Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental group
- **DRUG:** Basiliximab injected both control group and experimental group

## Key facts

- **NCT ID:** NCT01817322
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2014-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01817322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01817322, "Kidney Graft Function Under the Immunosuppression Strategies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01817322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*